Authors

Latest:

Dr. Albain Discusses Race-Based Breast Cancer Study Within TAILORx

Kathy S. Albain, MD, director, Breast Clinical Research Program, co-director, Breast Oncology Center, professor of medicine, Stritch School of Medicine, Loyola University Chicago, discusses a race-based study within the TAILORx trial.

Kathy W. Oubre, MS

Latest:

It Takes a Village, Not a Navigator

Pontchartrain Cancer Center was faced with the same dilemma most community-based independents have dealt with: reinvent the practice or join a hospital.

Katie Eder

Latest:

Cancer-Related Pain Fraught With Therapeutic and Ethical Complexities

As long-term cancer survival rates continue to surge, an increasing percentage of patients with cancer-related pain are progressing to the chronic pain arena, which necessitates more contemporary treatment approaches to cancer pain management.

Katie Hay

Latest:

Adapt Healthcare Skills to Meet Cancer Needs of LGBT Community

Cancer doesnâ€™t discriminate, but that doesnâ€™t mean the healthcare system wonâ€™t. This proves to be even more true for the lesbian, gay, bisexual and transgender community.

Katie Kelley, MD, Hellen Diller Family Comprehensive Cancer Center

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Katie Kerrigan, DO

Latest:

Incorporating PROs Can Improve Patient Care and Outcomes in Oncology

Karnofsky Performance Status and ECOG performance status alone leaves a lot to be desired for the practicing oncologist.

Katie Kerrigan, MD

Latest:

Dr. Kerrigan on Sequencing Challenges in ALK+ NSCLC

Katie Kerrigan, MD, discusses sequencing challenges in the treatment of patients with ALK-positive non–small cell lung cancer.

Katie Kosko

Latest:

Immunotherapy Combinations Deliver Outcome-Shifting Responses in Lymphoma

Immunotherapy has become a valuable tool for the treatment of patients with various types of lymphomas because of its ability to specifically target cancer cells, particularly those in blood cancers.

Katie Kosko & Tony Hagen

Latest:

Cures Act Moves Step Closer to Adoption With Senate Approval

The sweeping, $6.3 billion 21st Century Cures Act, designed to create a 10-year pool of money for precision medicine development and social health initiatives, gained overwhelming Senate approval Wednesday and goes next to President Obama, who has said he will sign the bill.

Katie Moore, MD, University of Oklahoma

Katina Robison, MD

Latest:

Moving Beyond Standard of Care: Novel Treatments in Gynecologic Cancer

In the United States, gynecologic cancers affect nearly 80,000 women annually and are the cause of death in more than 25,000 women.

Katja Weisel, MD

Latest:

Unmet Needs in the Management of Multiple Myeloma

Sagar Lonial, MD, provides insight on mechanisms of resistance to CAR T-cell therapies, and the panel shares unmet needs and future directions for the treatment of multiple myeloma.

Katsuhiko Uesaka, MD, PhD

Latest:

Dr. Uesaka on Gemcitabine vs S-1 in Pancreatic Cancer

Katsuhiko Uesaka, MD, PhD, from the Shizuoka Cancer Center Hospital in Japan, discusses the JASPAC-01 study that compared gemcitabine to S-1 in Asian patients with resected pancreatic cancer.

Kaushal Parikh, MD, MBBS

Latest:

Dr Parikh on the Impact of the ADAURA and ALINA Trials on Early-Stage NSCLC Management

Kaushal Parikh, MBBS, discusses how data from the ADAURA and ALINA trials have advanced the management of early-stage non–small cell lung cancer.

Kavita Patel, MD, MS

Latest:

Dr. Patel Discusses the Cancer Drug Coverage Parity Act

Kavita Patel, MD, MS, policy analyst, Brookings Institution, discusses the Cancer Drug Coverage Parity Act.

Kavitha Ramchandran, MD

Latest:

Dr. Ramchandran on Considerations for Palliative Care in Thoracic Cancers

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Kazuhiko Nakagawa, MD, PhD

Latest:

Dr. Nagawaka Discusses Findings of the RELAY Trial in EGFR+ NSCLC

Kazuhiko Nakagawa, MD, PhD, Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan, discusses findings of the RELAY trial in EGFR-positive non–small cell lung cancer.

Kebede H. Begna, MD

Latest:

Dr. Begna on Recent Advancements in MPNs

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Keerthi Gogineni, MD

Latest:

Dr. Gogineni on the Efficacy of CDK4/6 Inhibitors Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

Keerthi Gogineni, MD, MSHP, discusses the efficacy of CDK4/6 inhibitors plus endocrine therapy in patients with hormone receptor–positive, HER2-negative early breast cancer.

Keerthi Gogineni, MD, MSHP

Latest:

Dr. Gogineni on Implications of the APT Trial in HER2+ Breast Cancer

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.